The FLOWERS Phase 2 trial, published in Nature Communications, reported that osimertinib with or without savolitinib showed efficacy in EGFR‑mutant NSCLC patients with MET aberrations, providing evidence for tailored combination strategies in this molecular subgroup. The data refine patient selection and dosing considerations for EGFR/MET‑co‑altered tumors. In a final analysis of the MOUNTAINEER trial, tucatinib plus trastuzumab demonstrated efficacy in HER2‑positive metastatic colorectal cancer and supported the regimen’s activity in a difficult‑to‑treat population. The results expand tucatinib’s utility beyond breast cancer into other HER2‑driven solid tumors. Both readouts provide clinically actionable evidence for targeted combination approaches and could shape near‑term trial design and regulatory discussions for biomarker‑selected patient populations.